NanoLogix Inc. announced its R&D team in collaboration with University Of Texas Health Science Center At Houston (UTHSC-Houston) researchers, are developing a multi-well, microplate reader variant of the company's BioNanoFilter (BNF) diagnostics for use in large volume laboratory environments. Early analysis of the multi-well plates shows exceptionally fast live-threat results similar to the company's standard BNF technology. Data showed NanoLogix diagnostics consistently provided results in a 4 to 6 hour window, dramatically shorter than standard culturing times of 48 to 72 hours. The data and the associated clinical study narrative are currently being formatted for submission for peer-review publication, as well as to the US FDA for acceptance as a non-invasive diagnostic technology. Rapid Live-Threat Tuberculosis Results: Recent R&D operations have also converged to dramatically enrich NanoLogix' bacteria and protozoa detection technology portfolio. The detection for Tuberculosis (TB) utilizing NanoLogix' BNF and BioNanoPore (BNP) technologies has recently been completed by a major independent, third-party research laboratory. Live-threat TB was detected with NanoLogix BNP technology in 4 to 5 days, as opposed to 21 to 84 days with standard culture. TB was also detected and identified with the company's BNF technology in less than two hours. Peer-reviewed publication and FDA submittal are in process for results from both BNP and BNF Tuberculosis research.